SAN
JOSE, Calif., Sept. 12,
2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:
ANIX), a biotechnology company focused on the treatment and
prevention of cancer and infectious diseases, today announced that
the inventor of its ovarian cancer CAR-T technology, Dr.
Jose Conejo-Garcia, Senior Member of
the Immunology Department at Moffitt Cancer Center, will be
speaking at the Rivkin Center and American Association for Cancer
Research (AACR) 14th Biennial Ovarian Cancer Research
Symposium. The symposium will include a seminar on immuno-oncology
on Wednesday, September 28, 2022, at
which Dr. Conejo-Garcia is an invited lecturer.
During the presentation, Dr. Conejo-Garcia will discuss the
CAR-T technology, which is an autologous cell therapy comprised of
engineered T-cells that target the follicle stimulating hormone
receptor (FSHR). FSHR is found at immunologically relevant levels
exclusively on the granulosa cells of the ovaries. Since the target
is a hormone receptor, and the target-binding domain is derived
from its natural ligand, this technology is also known as CER-T
(Chimeric Endocrine Receptor T-cell) therapy, a new type of CAR-T.
Dr. Conejo-Garcia will also discuss the ongoing Phase 1 clinical
trial of this technology.
"I am excited to discuss our novel FSHR-mediated CAR-T
technology at this seminar series and to share ideas and advance
the field of ovarian cancer research," stated Dr. Conejo-Garcia.
"Moffitt and Anixa have been working together to advance this
ovarian cancer therapy and we are thrilled to have treated the
first patient in our ongoing clinical trial. If this therapeutic
approach is successful, this could enable a major shift in the
overall treatment paradigm for ovarian cancer."
More information about the event may be found at:
https://rivkin.org/symposia/ocrs/.
About Anixa Biosciences,
Inc.
Anixa is a clinical-stage biotechnology company with a number of
programs addressing cancer and infectious disease. Anixa's
portfolio of therapeutics includes a cancer immunotherapy program
being developed in collaboration with Moffitt Cancer Center, which
uses a novel type of CAR-T, known as chimeric endocrine receptor
T-cell (CER-T) technology, and, with partner MolGenie GmbH, a
COVID-19 program focused on compounds targeting the Mpro
enzyme of SARS-CoV-2, which is largely conserved across all
recently identified variants. The company's vaccine portfolio
includes a novel vaccine being developed in collaboration with
Cleveland Clinic to prevent breast cancer – specifically triple
negative breast cancer (TNBC), the most lethal form of the disease
– as well as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on clinical development allows the company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn and
Facebook.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the words
"believes," "expects," "intends," "plans," "anticipates," "likely,"
"will" and similar expressions to identify forward-looking
statements. Such forward-looking statements, including those
concerning our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike
Catelani
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-ovarian-cancer-car-t-therapy-to-be-presented-at-the-rivkin-center--american-association-of-cancer-research-aacr-14th-biennial-ovarian-cancer-research-symposium-301621773.html
SOURCE Anixa Biosciences, Inc.